Michael B. Mann - Thousand Oaks CA, US Randy Ira Hecht - Thousand Oaks CA, US Mary Ann Pelleymounter - San Diego CA, US Christopher Francis Toombs - Camarillo CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07H021/04 C12P021/00 C12N001/20 C12N015/16
US Classification:
435 691, 4352523, 4353201, 536 234
Abstract:
The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
Michael B. Mann - Thousand Oaks CA, US Randy Ira Hecht - Thousand Oaks CA, US Mary Ann Pelleymounter - San Diego CA, US Christopher Francis Toombs - Camarillo CA, US
Assignee:
Amgen, Inc. - Thousand Oaks CA
International Classification:
C07K 16/46 A61K 38/27 A61K 38/18
US Classification:
530350, 5303873, 530399
Abstract:
The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
Mary Ann Pelleymounter - Thousand Oaks CA, US Randy Ira Hecht - Thousand Oaks CA, US Michael Benjamin Mann - Thousand Oaks CA, US
Assignee:
Amgen, Inc. - Thousand Oaks CA
International Classification:
C07K 1/14 C07K 14/00
US Classification:
530412, 530350, 530228
Abstract:
The present invention provides methods and compositions for treating excess weight by administering OB protein in a form for constant supply, at a dosage of less than or equal to about 1 mg protein/kg body weight/day. Compositions and methods used for production of recombinant murine and human OB protein are also provided. Compositions and methods for preparing recombinant murine methionyl OB protein and recombinant human methionyl OB protein, including DNA sequences, vectors, host cells, methods of fermentation, and methods of purification are provided herein.
Fgf21 Polypeptides Comprising Two Or More Mutations
Edward John Belouski - Camarillo CA, US Murielle Marie Ellison - Thousand Oaks CA, US Agnes Eva Hamburger - Newbury Park CA, US Randy Ira Hecht - Thousand Oaks CA, US Yue-Sheng Li - Thousand Oaks CA, US Mark Leo Michaels - Encino CA, US Jeonghoon Sun - Thousand Oaks CA, US Jing Xu - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 38/18 C07K 14/50
US Classification:
514 91, 530350, 530399
Abstract:
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Michael B. Mann - Thousand Oaks CA, US Randy Ira Hecht - Thousand Oaks CA, US Mary Ann Pellymounter - San Diego CA, US Christopher Francis Toombs - Camarillo CA, US
The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
Edward John Belouski - Camarillo CA, US Murielle Marie Ellison - Thousand Oaks CA, US Agnes Eva Hamburger - Thousand Oaks CA, US Randy Ira Hecht - Thousand Oaks CA, US Yue-Sheng Li - Thousand Oaks CA, US Mark Leo Michaels - Encino CA, US Jeonghoon Sun - Thousand Oaks CA, US Jing Xu - Thousand Oaks CA, US
Edward John Belouski - Camarillo CA, US Murielle Marie Ellison - Thousand Oaks CA, US Agnes Eva Hamburger - Newbury Park CA, US Randy Ira Hecht - Thousand Oaks CA, US Yue-Sheng Li - Thousand Oaks CA, US Mark Leo Michaels - Encino CA, US Jeonghoon Sun - Thousand Oaks CA, US Jing Xu - Thousand Oaks CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
A61K 38/18 C07K 14/50
US Classification:
514 91, 530350, 530399
Abstract:
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Edward John Belouski - Camarillo CA, US Murielle Marie Ellison - Thousand Oaks CA, US Agnes Eva Hamburger - Newbury Park CA, US Randy Ira Hecht - Thousand Oaks CA, US Yue-Sheng Li - Thousand Oaks CA, US Mark Leo Michaels - Encino CA, US Jeonghoon Sun - Thousand Oaks CA, US Jing Xu - Thousand Oaks CA, US
R & R Biotech Consulting
President
Biopharma Industry Jan 1977 - Dec 2011
Scientific Director
Amgen Feb 1992 - Dec 2011
Scientific Director of Protein Sciences
Monsanto Company 1983 - 1992
Research Specialist
Skills:
Biotechnology Protein Chemistry Biochemistry Chromatography Pharmaceutical Industry Hplc Purification Biopharmaceuticals Life Sciences Antibodies Technology Transfer Drug Discovery Clinical Trials Gmp Analytical Chemistry Commercialization Molecular Biology Cell Fda Drug Development Cell Culture Validation Cell Biology Genomics Protein Engineering Process Simulation Lifesciences Glp Characterization Sop Recombinant Dna Technology Immunology Vaccines Clinical Development Peptides Sequencing Microbiology Research and Development Monoclonal Antibodies Oncology Science Cancer Toxicology Infectious Diseases Protein Purification U.s. Food and Drug Administration R&D
Randy Hecht 1983 graduate of Oceanside High School in Oceanside, NY is on Classmates.com. See pictures, plan your class reunion and get caught up with Randy and other high school ...